Ambit Health Ventures
VC Fund
Ambit Health Ventures is a healthcare venture capital firm that focuses on investments in early-stage digital health and MedTech firms. It aims to improve healthcare through their portfolio companies’ innovation while achieving financial gain for its investors.
- Total investments:
- 10
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Ambit Health Ventures invests in
Health CareMedicalMedical DeviceSaaSmHealth
Stages Ambit Health Ventures invests in
SeedSeries AFunding Round
Countries Ambit Health Ventures invests in
United States
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Sam Goldberger
|
|||
4 more contacts available
Investment Focus
Industry
- Health Care 4 (40%)
- Medical 3 (30%)
- Medical Device 2 (20%)
- SaaS 1 (10%)
- mHealth 1 (10%)
Stage
- Seed 3 (30%)
- Series A 1 (10%)
- Funding Round 1 (10%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Sam Goldberger
Managing Partner and Co-Founder
|
Managing Partner and Co-Founder | Total investments: 7 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Osteoboost
|
Bone Health Technologies specializes in developing medical devices designed for low bone mass. Its solution is a gentle mechanical stimulation that mimics weight-bearing exercise, providing an effective non-drug intervention. It offers the OsteoBoost device that relies on safe, natural, and effective whole-body vibration technology usingvibrational energy to turn stem cells into the bone using the same mechanisms as physical exercise. The company was founded in 2018 and is headquartered in San Francisco, California. | $8M / Series A / Apr 09, 2026 | |
Smartlens
|
Smartlens is a clinical-stage Med Tech company with a portfolio of technologies to treat and diagnose Glaucoma - a chronic eye disease and the leading cause of irreversible blindness. The Company is running clinical trials with its novel eye pressure (IOP) monitoring contact lens (miLens) that will help improve clinical outcomes in Glaucoma. Thedisease affects hundreds of millions around the globe; even in developed countries more than 50% of the patients are currently undiagnosed, and more than 38% are going blind despite being treated. The need for monitoring eye pressure outside the clinic has been defined as an urgent need by scientific, medical, and industry leaders in ophthalmology that will help improve clinical outcomes. Smartlens’ flagship product miLens is a non-invasive and convenient way of monitoring eye pressure for anyone anywhere at any time. It will help improve early diagnosis, enable personalized treatments, and disease monitoring thus reducing the prevalence of blindness, treatment costs, and its huge burden on lives and economies. miLens is utilizing a novel, electronics-free sensor technology that is fully owned by Smartlens, Inc. and protected by its portfolio of issued and pending patents covering more than 40 countries. The Company's novel technology is also being studied at Stanford University Labs for monitoring (ICP) which is associated with certain neurological disorders, and cancers. Smartlens also owns a non-invasive drug delivery technology that monitors the IOP and releases the right medication at the right time which will help improve efficacy, patient compliance and reduce the side effects. Smartlens is the Winner of the 2021 "Outstanding Innovation in Medical Technology and Life Sciences" of High-Tech Awards by Octane. The Company has been invited to various national and international conferences, published its studies, listed among the Top 10 MedTech Startups, and featured in ABC7, Fortune, BBC, and Nature Medicine. | $5.2M / Venture - Series Unknown / Oct 14, 2025 | |
Encapsulate
|
Producing an effective chemotherapy solution with a fully automated tumor-on-a-chip, pre-prescription analysis. | $1.8M / Seed / Jun 01, 2024 | |
Wavely Diagnostics
|
Wavely Diagnostics is pioneering the future of remote digital diagnostics and enabling telehealth growth by leveraging smartphone technology to address pediatric care. | $1.4M / Seed / Jul 12, 2023 | |
|
Smartlens
|
Smartlens is a clinical-stage Med Tech company with a portfolio of technologies to treat and diagnose Glaucoma - a chronic eye disease and the leading cause of irreversible blindness. The Company is running clinical trials with its novel eye pressure (IOP) monitoring contact lens (miLens) that will help improve clinical outcomes in Glaucoma. Thedisease affects hundreds of millions around the globe; even in developed countries more than 50% of the patients are currently undiagnosed, and more than 38% are going blind despite being treated. The need for monitoring eye pressure outside the clinic has been defined as an urgent need by scientific, medical, and industry leaders in ophthalmology that will help improve clinical outcomes. Smartlens’ flagship product miLens is a non-invasive and convenient way of monitoring eye pressure for anyone anywhere at any time. It will help improve early diagnosis, enable personalized treatments, and disease monitoring thus reducing the prevalence of blindness, treatment costs, and its huge burden on lives and economies. miLens is utilizing a novel, electronics-free sensor technology that is fully owned by Smartlens, Inc. and protected by its portfolio of issued and pending patents covering more than 40 countries. The Company's novel technology is also being studied at Stanford University Labs for monitoring (ICP) which is associated with certain neurological disorders, and cancers. Smartlens also owns a non-invasive drug delivery technology that monitors the IOP and releases the right medication at the right time which will help improve efficacy, patient compliance and reduce the side effects. Smartlens is the Winner of the 2021 "Outstanding Innovation in Medical Technology and Life Sciences" of High-Tech Awards by Octane. The Company has been invited to various national and international conferences, published its studies, listed among the Top 10 MedTech Startups, and featured in ABC7, Fortune, BBC, and Nature Medicine. | $6.1M / Series A / Jul 11, 2023 | |
SOAP Health
|
SOAP helps patients and physicians make better decisions by capturing and analyzing detailed patient data pre-visit, offering augmented intelligence at the point of care, graphically representing risk, and providing actionable insights to improve clinical decision-making. It identifies, verifies, and simplifies accurate and completepatient-reported data collection, risk assessment, documentation, and electronic delivery to physicians in a 90% completed SOAP (Subjective, Objective, Assessment, Plan) Note to improve patient care and doctor productivity, and decrease liability exposure.The company was founded in 2019 and is based in Boca Raton, Florida. | $2M / Seed / Sep 22, 2022 | |
|
Wavely Diagnostics
|
Wavely Diagnostics is pioneering the future of remote digital diagnostics and enabling telehealth growth by leveraging smartphone technology to address pediatric care. | $2.2M / Seed / Feb 08, 2022 | |
|
Smartlens
|
Smartlens is a clinical-stage Med Tech company with a portfolio of technologies to treat and diagnose Glaucoma - a chronic eye disease and the leading cause of irreversible blindness. The Company is running clinical trials with its novel eye pressure (IOP) monitoring contact lens (miLens) that will help improve clinical outcomes in Glaucoma. Thedisease affects hundreds of millions around the globe; even in developed countries more than 50% of the patients are currently undiagnosed, and more than 38% are going blind despite being treated. The need for monitoring eye pressure outside the clinic has been defined as an urgent need by scientific, medical, and industry leaders in ophthalmology that will help improve clinical outcomes. Smartlens’ flagship product miLens is a non-invasive and convenient way of monitoring eye pressure for anyone anywhere at any time. It will help improve early diagnosis, enable personalized treatments, and disease monitoring thus reducing the prevalence of blindness, treatment costs, and its huge burden on lives and economies. miLens is utilizing a novel, electronics-free sensor technology that is fully owned by Smartlens, Inc. and protected by its portfolio of issued and pending patents covering more than 40 countries. The Company's novel technology is also being studied at Stanford University Labs for monitoring (ICP) which is associated with certain neurological disorders, and cancers. Smartlens also owns a non-invasive drug delivery technology that monitors the IOP and releases the right medication at the right time which will help improve efficacy, patient compliance and reduce the side effects. Smartlens is the Winner of the 2021 "Outstanding Innovation in Medical Technology and Life Sciences" of High-Tech Awards by Octane. The Company has been invited to various national and international conferences, published its studies, listed among the Top 10 MedTech Startups, and featured in ABC7, Fortune, BBC, and Nature Medicine. | Seed / Dec 01, 2021 | |
|
Osteoboost
|
Bone Health Technologies specializes in developing medical devices designed for low bone mass. Its solution is a gentle mechanical stimulation that mimics weight-bearing exercise, providing an effective non-drug intervention. It offers the OsteoBoost device that relies on safe, natural, and effective whole-body vibration technology usingvibrational energy to turn stem cells into the bone using the same mechanisms as physical exercise. The company was founded in 2018 and is headquartered in San Francisco, California. | $2.5M / May 05, 2021 | |
|
Osteoboost
|
Bone Health Technologies specializes in developing medical devices designed for low bone mass. Its solution is a gentle mechanical stimulation that mimics weight-bearing exercise, providing an effective non-drug intervention. It offers the OsteoBoost device that relies on safe, natural, and effective whole-body vibration technology usingvibrational energy to turn stem cells into the bone using the same mechanisms as physical exercise. The company was founded in 2018 and is headquartered in San Francisco, California. | Series A |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
SaaS Investors
99,274 investors
Health Care Investors
43,014 investors
Medical Investors
18,848 investors
Medical Device Investors
11,047 investors
SaaS VC Funds
61,208 investors
Health Care VC Funds
32,370 investors
Medical VC Funds
16,214 investors
Medical Device VC Funds
9,894 investors
SaaS Investors in United States
47,640 investors
FAQ
What does Ambit Health Ventures invest in?
Ambit Health Ventures invests primarily in Health Care, Medical and Medical Device startups, most often at Seed and Series A stage. Most of the 10 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Ambit Health Ventures?
For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Ambit Health Ventures?
The team at Ambit Health Ventures includes Sam Goldberger (Managing Partner and Co-Founder). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
